Harnessing innate mechanisms to transport diverse large-molecule cargoes across the blood-brain barrier
The MODEL platform
At the foundation of the Modular Delivery (MODEL) platform are small modular protein domains with optimized developability and stability. Originally designed by Janssen researchers, the platform is engineered for both efficient BBB transport and downstream therapeutic functionality. The MODEL platform is being applied and extended by Aliada to multiple targets and modalities.
Efficient transport
Modules are carried with their cargoes across the BBB via native transcytosis pathways responsible for moving iron or amino acids into the brain, leading to greater exposure.
Fit-for-purpose toolkit
MODEL allows for the generation of fit-for-purpose therapeutics. The platform includes a toolkit that enables tailoring of exposure and flexibility of therapeutic function, including two distinct BBB-receptor targets (TfR and CD98) and a design that can accommodate a variety of therapeutic cargoes.
ALIA-1758
Our platform-enabled lead program, a differentiated bispecific antibody targeting pyroglutamate amyloid beta (3pE-Aβ) and TfR, is being investigated for its potential to clear amyloid beta plaques from the brain more effectively and with improved convenience compared to currently available treatments.
A history of collaboration
Our team brings together decades of experience in the building of neuroscience-focused companies. Our goal is to broadly advance the delivery of large molecules across the blood-brain barrier to achieve our shared vision of opening the brain to current and future generations of innovative therapeutics.